Urgent.News

What's breaking now, across thousands of outlets.

Business

SK Biopharma Unveils Growth Blueprint

Lee Dong-hoon, president of SK Biopharmaceuticals, presented the strategy on Nov. 17 local time at the Jefferies Global Healthcare Conference in London, the United Kingdom. SK Biopharmaceuticals, the only South Korean pharmaceutical or biotech company to give an on-site presentation, attended the ev

On November 17th, Lee Dong-hoon, the president of SK Biopharmaceuticals, unveiled the company's growth strategy at the Jefferies Global Healthcare Conference in London, marking its fourth consecutive year of attendance. SK Biopharmaceuticals, the sole South Korean pharmaceutical or biotech firm to present, showcased its core asset, cenobamate, which has witnessed a surge in prescribing, reaching over 300,000 patients globally since September.

To navigate the product lifecycle, the company is targeting broader indications and age groups, including generalized tonic-clonic seizures in patients 12 and older, as well as pediatric patients. In addition, SK Biopharmaceuticals aims to enhance patient convenience by introducing diversified formulations, such as an oral suspension.

The company's expansion into global markets is accelerating. Following the start of commercialization in China in March, cenobamate was launched in South Korea and Japan in November, establishing a sales network across the three Northeast Asian countries. SK Biopharmaceuticals has also sequentially introduced the product in Peru, Chile, and Brazil in Central and South America.

To bolster its central nervous system portfolio, SK Biopharmaceuticals is developing the epilepsy candidate, Opcalim, which it in-licensed in August. The drug is currently in Phase 2/3 clinical trials, with key results anticipated in the second half of the year. Key growth drivers identified by the company include oncology, leveraging next-generation modalities such as RNA-programmable therapy (RPT) and targeted protein degradation (TPD).

The company plans to leverage its existing central nervous system research capabilities to explore oncology and uncover new therapeutic targets.

Additionally, SK Biopharmaceuticals announced the 'East-West Bridge' strategy, focusing on identifying promising technologies from Asian biotech companies and connecting them to global markets. Lee Dong-hoon highlighted the successful U.S. commercialization of cenobamate and emphasized the company's commitment to utilizing AI and open innovation to expedite the development of new drugs.

Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at businesskorea.co.kr →

More in Business

More from Wednesday 18 November →